Page last updated: 2024-11-05

troglitazone and Bone Diseases, Metabolic

troglitazone has been researched along with Bone Diseases, Metabolic in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.

Research Excerpts

ExcerptRelevanceReference
"Troglitazone was less effective in controlling serum cholesterol and neuropathy."1.31Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nuttall, ME1
Patton, AJ1
Olivera, DL1
Nadeau, DP1
Gowen, M1
Shibata, T1
Takeuchi, S1
Yokota, S1
Kakimoto, K1
Yonemori, F1
Wakitani, K1

Other Studies

2 other studies available for troglitazone and Bone Diseases, Metabolic

ArticleYear
Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:3

    Topics: 1-Methyl-3-isobutylxanthine; Adipocytes; Alkaline Phosphatase; Animals; Apolipoproteins; Bone Diseas

1998
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
    British journal of pharmacology, 2000, Volume: 130, Issue:3

    Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro

2000